Objective: To appraise whether adverse events following oral implant placement may be associated with peri-operative use of non-steroidal anti-inflammatory drugs (NSAIDs). Methods: All patients with recorded implant failures between 1979 and 2012 in the Implant Prosthodontics Unit were contacted to solicit additional information about potential peri-operative use of NSAIDs. Results: From a total of 168 patients with 292 implant failures between 1979 and 2012, 122 consented to participate and had intact records. Just over half (56.6%) reported no peri-operative NSAID usage. However, compared to patients who did not use peri-operative NSAIDs, four times as many had complicated medical histories and twice as many patients taking NSAIDs suffered multiple implant failures. Conclusions: Patients with a variety of systemic diseases may be adversely affected by the inhibitory effect of NSAIDs on bone healing. Further prospective clinical studies are warranted to clarify this potential causative relationship in humans.

Objective: To appraise whether adverse events following oral implant placement may be associated with peri-operative use of non-steroidal anti-inflammatory drugs (NSAIDs). Methods: All patients with recorded implant failures between 1979 and 2012 in the Implant Prosthodontics Unit were contacted to solicit additional information about potential peri-operative use of NSAIDs. Results: From a total of 168 patients with 292 implant failures between 1979 and 2012, 122 consented to participate and had intact records. Just over half (56.6%) reported no peri-operative NSAID usage. However, compared to patients who did not use peri-operative NSAIDs, four times as many had complicated medical histories and twice as many patients taking NSAIDs suffered multiple implant failures. Conclusions: Patients with a variety of systemic diseases may be adversely affected by the inhibitory effect of NSAIDs on bone healing. Further prospective clinical studies are warranted to clarify this potential causative relationship in humans.

Thesis (Ph.D. in Toxicology) -- University of Colorado Denver, 2007. / Typescript. Includes bibliographical references (leaves 156-176). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;

Thesis (M.S.)--University of Michigan, 1993.

Orientador: Ney Carter do Carmo Borges / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-18T22:09:06Z (GMT). No. of bitstreams: 1 Rigato_HamiltonModesto_D.pdf: 6113608 bytes, checksum: 50f727cd3e6ffa2e40c62a248f3e7fea (MD5) Previous issue date: 2011 / Resumo: Objetivo: O presente trabalho teve por objetivo avaliar o perfil farmacocinético do diclofenaco de colestiramina (cápsula de 140mg) e de duas apresentações farmacêuticas (comprimidos 100mg e suspensão oral 50mg/mL) de nimesulide realizado em voluntários sadios de ambos os sexos e relacioná-los aos desfechos clínicos em enzimas do painel hepático e da contagem de plaquetas. Materiais e métodos: Os estudos foram do tipo aberto, aleatório, cruzado, em dois períodos. As amostras de sangue foram analisadas em cromatografia líquida de alta eficiência acoplada, a um detector de ultravioleta (UV) para o primeiro fármaco, e a um espectrômetro de massa (EM/EM) para outro. Os valores séricos do painel hepático e contagem de plaquetas foram comparados pré e pós-medicação. Resultados: As razões geométricas e respectivos 90% do IC para a cápsula de diclofenado de colestiramina/Flotac® 140 mg foram 100.22% (84.99 - 118.19%) para a CMAX e 90,53% (82.86-98.91%) para a ASCULTIMO. Os valores para o comprimido de Nimesulide/Nisulid® 100mg foram 85.96% (77.54 - 95.30%) para a CMAX e 93.91% (84.42 - 104.46%) para a ASCULTIMO, e a formulação de suspensão oral de Nimesulide/Nisulid® 50mg/mL obteve 100.1% (91.05 - 110.15%) para CMAX e 107.7% (99.74 - 116.39%) para ASCULTIMO. Quanto ao desfecho clínico foi observada elevação significante no parâmetro de ALT para o diclofenaco de colestiramina e na formulação comprimido de nimesulide. A formulação de suspensão oral teve elevação significante para o parâmetro de ALP. Não foi observada diminuição na contagem de plaquetas. Conclusão: Considerando que 90% dos intervalos de confiança das razões de CMAX e ASCULTIMO, se encontram dentro de 80-125% do intervalo proposto pelo FDA e aceita pela ANVISA, concluiu-se que a formulação de cápsula de diclofenaco de colestiramina (140mg) e a formulação de suspensão oral (50mg/mL) de nimesulide são bioequivalentes em relação à taxa e extensão de absorção e que a formulação comprimido de nimesulide (100mg) não é bioequivalente ao Nisulid® com relação a taxa de absorção. Clinicamente os medicamentos se mostraram seguros mesmo apresentando alterações estatisticamente significantes nos parâmetros clínicos avaliados / Abstract: Objective: The present work aims to evaluation the pharmacokinetic profile of the diclofenac-cholestyramine (140mg capsule) and two pharmaceuticals formulations (100mg tablets and 50mg/m oral suspension) of nimesulide in healthy adult subjects related with clinic outcomes in the hepatic enzymes panel and platelet count. Method: The studies were open, randomized, simple crossover balanced with two periods. The blood samples were analyzed by high performance liquid chromatography coupled to ultraviolet detection in diclofenac formulations. For nimesulide a mass espectrometer was performed (MS/MS). Seric enzymes from liver panels and whole blood platelet count was compared with pre and post single dose treatment. Results: The geometric mean and 90% confidence intervals (CI) for the diclofenac-cholestyramine/Flotac® ratio were 100.22% (84.99 - 118.19%) for CMAX and 90,53% (82.86-98.91%) for AUCLAST. The geometric mean and 90% confidence intervals (CI) for the Nimesulide/Nisulid® 100mg tablet were 85.96% (77.54 - 95.30%) for CMAX and 93.91% (84.42 - 104.46%) for AUCLAST, and for the oral suspension 50mg/mL were 100.1% (91.05 - 110.15%) for CMAX and 107.7% (99.74 - 116.39%) for AUCLAST. For the hepatic enzyme panel was observed significant rise in the ALT for diclofenac-cholestyramine and nimesulide tablet. The oral suspension was significant rise in the ALP parameter (p<0.05). No platelet count decrease was observed. Conclusion: Since the 90% CI for CMAX and AUCLAST ratios were all inside the 80-125% interval proposed by the US Food and Drug Administration and accepted by ANVISA, it is concluded that the diclofenac-cholestyramine 140mg capsule and the nimesulide oral suspension formulation 50mg/mL are bioequivalent in regard to both extent and rate of absorption. The nimesulide 100mg tablet is not bioequivalent to Nisulid® 100mg tablet with respect to the rate of absorption. Clinically all the evaluated pharmaceuticals are safety despide the significant changes in the hepatic enzymes panel observed / Doutorado / Ciencias Basicas / Doutor em Clínica Médica

The non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in Endodontics and when associated with some risk factors, such as concomitant use of other drugs, may develop undesirable and possibly serious effects. This cross-sectional study evaluated, through data collecting on dental records, potential interactions among the most commonly prescribed NSAIDs and medications used by patients treated in the Integrated Clinical Dentistry of UFSM, from 2007 to 2011. The data were processed on the EpiData and the statistical analysis was performed with SPSS Software. For analysis of interactions between drugs two tertiary bibliographic source were used: the book Drug Interaction Facts and computerized tool Drugdex in the Micromedex. Potential drug interactions with NSAIDs occurred with 20.2% of the drugs related by patients. The most common consequences in this context were gastrointestinal bleeding, decrease antihypertensive effect and renal failure. In relation to gravity and documentation of interaction, there was a higher frequency of the important gravity and well-documented in the issue of pharmacological interaction. Hence, special attention must be given to the elderly and other patients using several drugs at the same time alongside with educational initiatives focused on a more safe prescription method should be taught in educational institutions. / Os anti-inflamatórios não esteroides (AINEs) são fármacos amplamente utilizados em Endodontia e, quando associadas a alguns fatores de risco, como uso concomitante de outros medicamentos, podem desenvolver efeitos indesejados e possivelmente graves. Esse estudo transversal avaliou, por meio de uma coleta de dados nos prontuários odontológicos, as potenciais interações entre os AINEs mais comumente prescritos e os medicamentos em uso pelos pacientes atendidos nas Clínicas Integradas do Curso de Odontologia da UFSM, no período de 2007 a 2011. Os dados foram codificados no Programa EpiData e a análise estatística foi realizada com o Software SPSS. Para análise das interações entre os fármacos foram utilizadas duas fontes bibliográficas terciárias: o livro Drug Interaction Facts e a ferramenta informatizada Drugdex do Micromedex. As potenciais interações medicamentosas com AINEs ocorreram em 20,2% dos medicamentos relatados pelos pacientes. As consequências mais frequentes nesse contexto foram sangramento gastrointestinal, diminuição do efeito anti-hipertensivo e insuficiência renal. Em relação à gravidade e a documentação da interação, observou-se maior frequência de gravidade importante e bem documentada no quesito interação farmacológica. Então, atenção especial deve ser dada a pacientes idosos e outros pacientes que utilizem diversos medicamentos de forma paralela e iniciativas educacionais focadas em um método de prescrição mais seguro devem ser lecionadas em instituições de ensino.

Orientador: Deborah Queiroz de Freitas França / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba / Made available in DSpace on 2018-08-27T07:55:32Z (GMT). No. of bitstreams: 1 Yamasaki_MayraCristina_M.pdf: 2177440 bytes, checksum: 265b5bbb546beea3ceaf391cc126bc5a (MD5) Previous issue date: 2015 / Resumo: O presente estudo teve como objetivo avaliar o possível efeito radioprotetor do anti-inflamatório não esteroide meloxicam na prevenção da osteorradionecrose, na reparação alveolar e na resistência óssea em mandíbulas de ratos irradiados. Para isso, 40 ratos Wistar machos foram divididos em 4 grupos (n=10): controle (GC), irradiado (GI), meloxicam (GM) e meloxicam irradiado (GMI). Aos 75 dias de vida, foi administrado dose única de 0,2 mg/kg de meloxicam nos animais dos grupos GM e GMI. Uma hora depois, realizou-se a irradiação dos animais dos grupos GI e GMI com dose única de 15 Gy de radiação X na região de mandíbula. Decorridos 40 dias, foi realizado a exodontia bilateral dos primeiros molares inferiores nos animais, os quais foram mortos após 15 dias (n=5) e 30 dias (n=5). Utilizou-se a microtomografia computadorizada para avaliação da reparação alveolar, por meio da análise dos parâmetros da microestrutura trabecular óssea, como: volume tecidual total, volume ósseo, fração de volume ósseo, espessura trabecular média, número trabecular médio e separação trabecular média; e o teste de flexão para a avaliação da resistência óssea. A Análise de Variância um fator, com teste post hoc de Tukey, demonstrou que, aos 15 dias, o volume ósseo, a fração de volume ósseo e a espessura trabecular média foram significativamente superiores nos grupos GC e GM comparados aos grupos GI e GMI; já a separação trabecular média teve resultado estatístico inferior no grupo GI em relação aos demais. Aos 30 dias, houve diferença significante apenas na separação trabecular média, cujo resultado estatístico foi inferior no grupo GI em comparação aos grupos GC e GM, não tendo o grupo GMI diferido estatisticamente dos demais. Quanto à resistência óssea, o grupo GI foi significativamente inferior em relação aos grupos GC e GM, não tendo o grupo GMI diferido estatisticamente dos demais. Concluiu-se, assim, que foi observado ausência de osteorradionecrose clínica e que o meloxicam, embora não tenha demonstrado evidente efeito radioprotetor, apresentou efeito positivo na separação trabecular média da microestrutura trabecular óssea da reparação alveolar e na resistência óssea / Abstract: The aim of this study was to evaluate the possible radioprotective effect of the non-steroidal anti-inflammatory drug meloxicam on the prevention of osteoradionecrosis, alveolar socket healing and bone strength in the mandibles of irradiated rats. Forty male Wistar rats were divided into 4 groups (n=10): control (CG), irradiated (IG), meloxicam (MG), and meloxicam irradiated (MIG). When the animals were 75 days old, a single dose of 0.2 mg/kg meloxicam was administered to the animals in the MG and MIG groups. One hour later, the animals in the IG and MIG groups were irradiated with a single 15 Gy dose of X-rays in the mandible region. Forty days later, the mandibular first molars were extracted bilaterally and the animals were killed after 15 days (n=5) or 30 days (n=5). Micro-computed tomography was used to evaluate healing in the alveolar socket; trabecular bone microarchitecture features such as total volume, bone volume, bone volume fraction, trabecular number, trabecular thickness and trabecular separation were assessed. A bending test was used to evaluate bone strength. At 15 days, the one-way analysis of variance, followed by post hoc comparisons with the Tukey test, demonstrated that bone volume, bone volume fraction and trabecular thickness were significantly higher in the CG and MG groups than in the IG and MIG groups; and trabecular separation had lower statistical result in the IG group in comparison with the other groups. At 30 days, there was a significant difference only in trabecular separation, which statistical result was lower in the IG group than in the CG and MG groups, and the MIG group did not differ statistically from the others. Bone strength was significantly lower in the IG group compared with the CG and MG groups, and the MIG group did not differ statistically from the others. Therefore, it was concluded that the absence of clinical osteoradionecrosis was observed and the meloxicam, even though it has not demonstrated a clear radioprotective effect, had a positive effect on the trabecular separation of trabecular bone microarchitecture in alveolar socket healing and the bone strength / Mestrado / Radiologia Odontologica / Mestra em Radiologia Odontológica

Ho Toi Sze Joyce. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 65-74). / Abstracts in English and Chinese. / Acknowledgement --- p.ii / Contents --- p.iii / Abstract --- p.viii / List of Abbreviations --- p.xvii / List of Tables --- p.xix / List of Figures --- p.xx / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- The role of Non-steroidal anti-inflammatory drugs (NSAIDs) --- p.1 / Chapter 1.2 --- NSAID-induced gastrointestinal (GI) toxicity --- p.1 / Chapter 1.2.1 --- Pathogenesis of NSAID-induced GI toxicity --- p.2 / Chapter 1.2.2 --- GI symptoms --- p.4 / Chapter 1.2.3 --- GI ulcers --- p.4 / Chapter 1.2.4 --- GI complications --- p.5 / Chapter 1.2.5 --- Risk factor for GI complications --- p.6 / Chapter 1.2.6 --- Ulcerogenicity of different NSAIDs in upper GI events --- p.6 / Chapter 1.3 --- Prevention of NSAID-induced GI toxicity --- p.7 / Chapter 1.3.1 --- H2-receptor antagonists --- p.8 / Chapter 1.3.2 --- Misoprostol --- p.8 / Chapter 1.3.3 --- Proton Pump Inhibitor (PPI) --- p.9 / Chapter 1.3.4 --- Selective COX-2 Inhibitors --- p.10 / Chapter 1.3.4.1 --- GI safety of selective COX-2 inhibitors --- p.11 / Chapter 1.3.4.1.1 --- Gastrointestinal outcomes research of rofecoxib --- p.13 / Chapter 1.3.4.1.2 --- Celecoxib Long term Arthritis Safety Study --- p.14 / Chapter 1.3.4.2 --- Cardiovascular toxicity of NSAIDs --- p.15 / Chapter 1.3.4.2.1 --- Cardiovascular toxicity of non-selective NSAIDs --- p.15 / Chapter 1.3.4.2.2 --- Cardiovascular toxicity of selective COX-2 inhibitors --- p.16 / Chapter 1.4 --- Guidelines on the management of osteoarthritis (OA) and rheumatoid arthritis (RA) --- p.21 / Chapter 1.4.1 --- American College of Rheumatology (ACR) Subcommittee --- p.22 / Chapter 1.4.2 --- National Institute for Clinical Excellence (NICE) --- p.23 / Chapter 1.4.3 --- Hong Kong Hospital Authority (HA) --- p.23 / Chapter 1.5 --- Cost of illness of upper GI events in the setting of an emergency room of a regional hospital in Hong Kong and cost analysis of selective COX-2 inhibitor with non-selective NSAID plus gastroprotective agent --- p.24 / Chapter 1.6 --- Objectives --- p.25 / Chapter Chapter 2 --- Cost of illness of upper GI events in the setting of an emergency room of a regional hospital in Hong Kong --- p.26 / Chapter 2.1 --- Methods --- p.28 / Chapter 2.1.1 --- Study site --- p.28 / Chapter 2.1.2 --- Cohort participants --- p.28 / Chapter 2.1.3 --- Resource data collection --- p.29 / Chapter 2.1.4 --- Cost data --- p.30 / Chapter 2.1.5 --- Statistical Methods --- p.31 / Chapter 2.1.6 --- Study perspective --- p.31 / Chapter 2.2 --- Results --- p.31 / Chapter 2.2.1 --- Demographic data --- p.31 / Chapter 2.2.2 --- Total direct medical cost of upper GI complaints in UCH --- p.33 / Chapter 2.3 --- Discussion --- p.35 / Chapter 2.3.1 --- Total direct medical cost of upper GI events --- p.35 / Chapter 2.3.2 --- Cost of upper GI events associated with NSAID usage --- p.38 / Chapter 2.3.3 --- Low dose aspirin on NSAID-induced GI toxicity --- p.38 / Chapter 2.3.4 --- Limitation --- p.39 / Chapter 2.3.5 --- Future study --- p.41 / Chapter 2.4 --- Conclusion --- p.41 / Chapter Chapter 3 --- Cost analysis of selective COX-2 inhibitor versus non-selective NSAID with gastroprotective agent --- p.43 / Chapter 3.1 --- Methods --- p.46 / Chapter 3.1.1 --- Local randomized clinical trial --- p.46 / Chapter 3.1.1.1 --- Study population --- p.46 / Chapter 3.1.1.2 --- Cost data --- p.47 / Chapter 3.1.1.3 --- Statistical Methods --- p.48 / Chapter 3.1.1.4 --- Sensitivity analysis --- p.49 / Chapter 3.1.2 --- Large randomized clinical trial --- p.49 / Chapter 3.1.2.1 --- Study population --- p.49 / Chapter 3.1.2.2 --- Cost data --- p.50 / Chapter 3.2 --- Results --- p.50 / Chapter 3.2.1 --- Local randomized clinical trial --- p.51 / Chapter 3.2.1.1 --- Demographic data --- p.51 / Chapter 3.2.1.2 --- Cost analysis --- p.52 / Chapter 3.2.1.3 --- Sensitivity analysis --- p.53 / Chapter 3.2.2 --- Large randomized clinical trial --- p.54 / Chapter 3.2.2.1 --- Demographic data --- p.54 / Chapter 3.2.2.2 --- Cost analysis --- p.55 / Chapter 3.3 --- Discussion --- p.55 / Chapter 3.3.1 --- Cost analysis --- p.55 / Chapter 3.3.2 --- Sensitivity analysis --- p.59 / Chapter 3.3.3 --- Low dose aspirin on NSAID-induced GI toxicity --- p.59 / Chapter 3.3.4 --- Limitation --- p.60 / Chapter 3.4 --- Future study --- p.62 / Chapter 3.5 --- Conclusion --- p.62 / Chapter Chapter 4 --- Conclusion --- p.63 / Chapter Chapter 5 --- Reference --- p.65 / Appendix Data collection form --- p.75

Diss. (sammanfattning) Linköping : Linköpings universitet, 2008. / Härtill 4 uppsatser.

Thesis (Ph. D.) -- University of Texas Southwestern Medical Center at Dallas, 2003. / Vita. Bibliography: 180-208.